Giant cell tumor of the tendon sheath (GCTTS) is a rare benign soft tissue tumor that is typically seen in the hand and wrist. It is an aggressive tumor that can cause significant pain and disability if not treated properly. The diagnosis of GCTTS can be challenging due to its rarity and lack of specific symptoms. This article will discuss the diagnosis and treatment of GCTTS, as well as the importance of early diagnosis and treatment.
GCTTS is a benign soft tissue tumor that is typically found in the hand and wrist. It is a rare condition, with an estimated incidence of 1.5 per 100,000 people. The tumor is composed of a mixture of fibroblasts, histiocytes, and multinucleated giant cells. It is typically located near the tendon sheath, but can also be found in other locations such as the fingers, palm, and forearm. The tumor can grow rapidly and cause significant pain and disability if not treated properly.
GCTTS typically presents with pain and swelling in the affected area. The pain may be localized or may radiate to other parts of the body. Other symptoms may include stiffness, numbness, tingling, and weakness. The tumor may cause a visible lump in the affected area.
The diagnosis of GCTTS is typically made based on the clinical presentation and imaging studies. Magnetic resonance imaging (MRI) is the most commonly used imaging modality for diagnosing GCTTS. It can be used to identify the tumor and its location, as well as any associated soft tissue changes. X-rays and ultrasound may also be used to confirm the diagnosis.
The treatment of GCTTS depends on the size and location of the tumor. Surgery is the most commonly used treatment for GCTTS. The goal of surgery is to remove the tumor and any associated tissue. If the tumor is small, it may be possible to remove it without damaging the surrounding tissue. If the tumor is large or located in an area that is difficult to access, it may be necessary to remove part of the tendon sheath or adjacent bone. Radiotherapy may also be used to treat GCTTS, either alone or in combination with surgery. Radiotherapy can be used to shrink the tumor and reduce the risk of recurrence. In some cases, chemotherapy may be used to treat GCTTS.
GCTTS is an aggressive tumor that can cause significant pain and disability if not treated properly. Early diagnosis and treatment is essential for successful management of GCTTS. Prompt diagnosis and treatment can help to reduce the risk of recurrence and improve the long-term outcome.
Giant cell tumor of the tendon sheath is a rare benign soft tissue tumor that is typically found in the hand and wrist. It can cause significant pain and disability if not treated properly. The diagnosis of GCTTS can be challenging due to its rarity and lack of specific symptoms. Early diagnosis and treatment is essential for successful management of GCTTS. Surgery is the most commonly used treatment for GCTTS, and radiotherapy and chemotherapy may also be used. It is important for doctors to be aware of the diagnosis and treatment of GCTTS in order to ensure the best possible outcome for their patients.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation